GSI Group Inc. — FY2012 Form 10-K
Entity note: The request metadata names NOVANTA INC., but the supplied filing is for GSI Group Inc. This summary follows the filing. The reporting period is the fiscal year ended December 31, 2012; selected fourth-quarter figures are also included.
Business context and reporting period
GSI designed, manufactured and sold laser-based solutions, optical control devices and precision technologies for electronics, industrial, medical and scientific markets. After classifying its Semiconductor Systems and Laser Systems businesses as discontinued operations in 2012, its continuing business comprised Laser Products and Precision Motion and Technologies. Prior-period figures were recast to reflect that presentation.
The company’s strategy emphasized growing medical components, scanning solutions and fiber lasers, while reducing reliance on microelectronics. In January 2013, after year-end, GSI acquired NDS Surgical Imaging for $82.5 million in cash.
Financial performance and liquidity
Amounts below are in U.S. dollars; financial statement amounts are in millions except per-share data.
| Metric | FY2012 | FY2011 |
|---|---|---|
| Continuing-operations sales | $271.5 | $304.3 |
| Gross profit / gross margin | $114.5 / 42.2% | $133.1 / 43.7% |
| Operating income / operating margin | $15.0 / 5.5% | $35.8 / 11.8% |
| Income from continuing operations | $22.5 | $21.7 |
| Net income attributable to GSI | $19.5 | $29.0 |
| Diluted EPS from continuing operations | $0.66 | $0.64 |
| Cash from operating activities | $28.4 | $45.2 |
- Sales declined 10.8%. Precision Motion and Technologies sales fell 14.7% to $163.3 million, chiefly on weaker microelectronics and PCB drilling demand; Laser Products sales fell 4.2% to $108.2 million.
- Laser Products gross margin declined to 33.8% from 38.9%, affected by product mix, fiber-laser costs and lower specialty-laser manufacturing absorption. Precision Motion and Technologies margin rose to 48.3% from 47.6%.
- Year-end cash and cash equivalents were $65.8 million, versus $54.8 million a year earlier. Operating cash flow was $28.4 million; investing activities provided $3.0 million, including $7.0 million from the Laser Systems asset sale, and financing activities used $21.1 million.
- Debt at year-end was $50.0 million, all under the term loan, with no revolving borrowings. The amended facilities provided a $75.0 million revolver and matured in December 2017. In January 2013, GSI drew $60.0 million to help fund NDS; the filing does not state a post-acquisition cash balance.
- At year-end, the company reported $208.5 million of current assets and $54.9 million of current liabilities. It was within debt covenants: leverage ratio 1.21 versus a 2.75 maximum, and fixed-charge coverage 2.72 versus a 1.50 minimum.
Material changes and unusual items
- Operating income fell 58.1% year over year, primarily from lower sales and $8.0 million in restructuring charges, compared with $2.0 million in 2011. The company also recorded $0.8 million of NDS-related acquisition costs.
- A $15.3 million release of deferred-tax valuation allowance contributed to a $10.9 million income-tax benefit for 2012. The benefit was non-cash; the effective tax rate was negative 94.9%.
- Discontinued operations reported $44.7 million of sales and a $5.2 million net loss in 2012, versus $62.0 million of sales and $7.3 million of net income in 2011. GSI recorded a $2.3 million net-of-tax gain on the Laser Systems asset sale.
- Fourth-quarter sales were $66.4 million and operating income was $3.3 million. The quarter included $14.9 million of continuing-operations income, largely reflecting a $12.35 million tax benefit, and $15.8 million of net income attributable to GSI, including the disposal gain.
- GSI expected $7–$8 million of 2013 capital expenditures and approximately $8.3 million of 2013 financing cash use, including scheduled term-loan and capital-lease payments. It reported no material property, plant and equipment purchase commitments.
Outlook, risks and contingencies
- Management said it did not expect a recovery in microelectronics markets in 2013. It planned to complete the Semiconductor Systems sale by the end of the second quarter of 2013 and sell the retained Orlando facility by year-end 2013.
- GSI expected the NDS acquisition to extend its medical-market reach and strengthen OEM relationships. However, one NDS surgical-display customer historically accounted for more than 10% of NDS revenue, creating customer-concentration risk.
- Key risks include cyclical customer capital spending, continued weakness in microelectronics, competitive and technology pressures, foreign-exchange exposure, supply-chain and manufacturing disruptions, regulatory requirements for medical products, and the ability to integrate NDS and complete planned divestitures.
- The UK and Japan defined-benefit plans were underfunded by approximately $6.1 million and $1.0 million, respectively. The French subsidiary receiver’s remaining tort claim sought approximately €3.1 million; management said a loss was not probable and recorded no accrual. The company also reported an IRS settlement agreement awaiting Joint Committee on Taxation consent.
- The filing reported an unqualified audit opinion and effective internal control over financial reporting as of December 31, 2012. GSI had a history of bankruptcy and past financial-statement restatements, relevant background when assessing reporting risk.
Important facts for investors to verify
- Confirm the issuer identity and ticker associated with this filing, given the metadata discrepancy.
- Track the completion, proceeds and remaining liabilities of the Semiconductor Systems divestiture and the sale of the Orlando property.
- Assess post-acquisition debt, available revolver capacity, cash generation and covenant headroom after the $60 million NDS-related draw.
- Monitor NDS customer concentration and whether the acquisition delivers the expected growth and integration benefits.
- Evaluate whether the 2012 tax benefit is sustainable and whether deferred-tax assets, tax disputes and pension funding assumptions remain supportable.